Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 3/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | XPO1 | O14980 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832709 | 0.86 | ALDH1A1 (0.37) | ALDH1A1MAPK1SMN1; SMN2KMOASPH | |
| SCHEMBL565623 | 0.84 | POLB (0.46) | ALDH1A1MAPK1SMN1; SMN2JUNNFKB1 | |
| SCHEMBL474007 | 0.83 | ALDH1A1 (0.46) | ALDH1A1MAPK1SMN1; SMN2KMOASPH | |
| SCHEMBL31337111 | 0.83 | CA1 (0.35) | ALDH1A1MAPK1SMN1; SMN2KMOJUN | |
| SCHEMBL29021390 | 0.83 | CA1 (0.35) | ALDH1A1MAPK1SMN1; SMN2KMOJUN | |
| SCHEMBL6357726 | 0.81 | NFKB1 (0.40) | ALDH1A1MAPK1SMN1; SMN2JUNNFKB1 | |
| SCHEMBL6357961 | 0.80 | JUN (0.33) | ALDH1A1MAPK1SMN1; SMN2JUNNFKB1 | |
| SCHEMBL6357963 | 0.80 | XPO1 (0.33) | ALDH1A1MAPK1SMN1; SMN2KMOJUN | |
| SCHEMBL6357967 | 0.80 | JUN (0.33) | ALDH1A1MAPK1SMN1; SMN2JUNNFKB1 | |
| SCHEMBL831077 | 0.80 | NOTUM (0.41) | ALDH1A1MAPK1SMN1; SMN2JUNNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115928113-B | Preparation method of 4-trifluoromethyl nicotinic acid | 山东京博农化科技股份有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-115928113-A | Preparation method of 4-trifluoromethyl nicotinic acid | 山东京博农化科技股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115928113-B | Preparation method of 4-trifluoromethyl nicotinic acid | 山东京博农化科技股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-115928113-B | Preparation method of 4-trifluoromethyl nicotinic acid | 山东京博农化科技股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2023062575-A1 | CYCLIC VINYL SULFONE COMPOUNDS AS WRN INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-115928113-A | Preparation method of 4-trifluoromethyl nicotinic acid | 山东京博农化科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115928113-A | Preparation method of 4-trifluoromethyl nicotinic acid | 山东京博农化科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-7109196-B2 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-24 | — | — | US | disclosed |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-6677352-B1 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027113-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1274683-A2 | HETEROCYCLIC ACYLSULFIMIDES, A METHOD FOR THEIR PRODUCTION, AGENTS CONTAINING THE SAME AND THEIR USE AS PESTICIDES | Bayer CropScience GmbH (DE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020032328-A1 | Heterocyclic acylsulfimides, processes for their preparation, compositions comprising them and their use as pesticides | AVENTIS CROPSCIENCE GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
| WO-2001070692-A2 | HETEROCYCLIC ACYLSULFIMIDES, A METHOD FOR THEIR PRODUCTION, AGENTS CONTAINING THE SAME AND THEIR USE AS PESTICIDES | BAYER CROPSCIENCE GMBH (DE) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | ALDH1A1 1855/4885MAPK1 1031/4885SMN1; SMN2 3345/4885 |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | UQCRC1, GLP1R, SLC5A1 | ALDH1A1 820/4885MAPK1 1071/4885SMN1; SMN2 3159/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | ALDH1A1 292/4885MAPK1 341/4885SMN1; SMN2 2135/4885 |
| US-20020032328-A1 | Heterocyclic acylsulfimides, processes for their preparation, compositions comprising them and their use as pesticides | DDT, PTMS, TMT1A | ALDH1A1 768/4885MAPK1 2174/4885SMN1; SMN2 1291/4885 |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, UQCRC1, SLC5A1 | ALDH1A1 1148/4885MAPK1 1389/4885SMN1; SMN2 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.